These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
83 related items for PubMed ID: 22936637
1. Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats. Vats R, Varanasi KV, Arla R, Veeraraghvan S, Rajak S. Biopharm Drug Dispos; 2012 Nov; 33(8):455-65. PubMed ID: 22936637 [Abstract] [Full Text] [Related]
2. Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats. Vats R, Varanasi KV, Arla R, Veeraraghavan S, Rajak S, Murthy AN. J Pharm Pharmacol; 2012 Nov; 64(11):1638-45. PubMed ID: 23058051 [Abstract] [Full Text] [Related]
3. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Lau YY, Okochi H, Huang Y, Benet LZ. Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870 [Abstract] [Full Text] [Related]
4. Effect of ciprofloxacin and grapefruit juice on oral pharmacokinetics of riluzole in Wistar rats. Ravi PR, Vats R, Kora UR. J Pharm Pharmacol; 2013 Mar; 65(3):337-44. PubMed ID: 23356842 [Abstract] [Full Text] [Related]
5. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Ryu KH, Han HY, Lee SY, Jeon SD, Im GJ, Lee BY, Kim K, Lim KM, Chung JH. Thromb Res; 2009 Jul; 124(3):328-34. PubMed ID: 19349067 [Abstract] [Full Text] [Related]
6. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO, Massaad R, Vandormael K. Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668 [Abstract] [Full Text] [Related]
7. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson TA. Am J Cardiol; 2004 Nov 01; 94(9):1140-6. PubMed ID: 15518608 [Abstract] [Full Text] [Related]
8. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Cruz-Fernández JM, Bedarida GV, Adgey J, Allen C, Johnson-Levonas AO, Massaad R. Int J Clin Pract; 2005 Jun 01; 59(6):619-27. PubMed ID: 15924587 [Abstract] [Full Text] [Related]
9. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. Lau YY, Okochi H, Huang Y, Benet LZ. J Pharmacol Exp Ther; 2006 Feb 01; 316(2):762-71. PubMed ID: 16258024 [Abstract] [Full Text] [Related]
10. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo. Kim CW, Yun JW, Bae IH, Park YH, Jeong YS, Park JW, Chung JH, Park YH, Lim KM. Thromb Res; 2011 Jun 01; 127(6):565-70. PubMed ID: 21420150 [Abstract] [Full Text] [Related]
11. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Cilla DD, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Clin Pharmacol Ther; 1996 Dec 01; 60(6):687-95. PubMed ID: 8988072 [Abstract] [Full Text] [Related]
12. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Penn R, Williams RX, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT. Clin Ther; 2006 Jan 01; 28(1):45-54. PubMed ID: 16490579 [Abstract] [Full Text] [Related]
13. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants. Shin KH, Yoon G, Yoon IS, Park JW. J Pharm Pharmacol; 2014 Jul 01; 66(7):961-74. PubMed ID: 24697278 [Abstract] [Full Text] [Related]
14. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Mitsios JV, Papathanasiou AI, Elisaf M, Goudevenos JA, Tselepis AD. Platelets; 2005 Aug 01; 16(5):287-92. PubMed ID: 16011979 [Abstract] [Full Text] [Related]
15. High-dose supplementation with natural α-tocopherol does neither alter the pharmacodynamics of atorvastatin nor its phase I metabolism in guinea pigs. Podszun MC, Grebenstein N, Hofmann U, Frank J. Toxicol Appl Pharmacol; 2013 Feb 01; 266(3):452-8. PubMed ID: 23200775 [Abstract] [Full Text] [Related]
18. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J. Cancer Chemother Pharmacol; 2012 Feb 01; 69(2):563-71. PubMed ID: 22057855 [Abstract] [Full Text] [Related]
20. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats. Choi DH, Chang KS, Hong SP, Choi JS, Han HK. Biopharm Drug Dispos; 2008 Jan 01; 29(1):45-50. PubMed ID: 17941000 [Abstract] [Full Text] [Related] Page: [Next] [New Search]